Literature DB >> 16630124

Cationized gelatin delivery of a plasmid DNA expressing small interference RNA for VEGF inhibits murine squamous cell carcinoma.

Goichi Matsumoto1, Toshihiro Kushibiki, Yukihiko Kinoshita, Ushaku Lee, Yasushi Omi, Eiro Kubota, Yasuhiko Tabata.   

Abstract

Double-stranded RNA (dsRNA) plays a major role in RNA interference (RNAi), a process in which segments of dsRNA are initially cleaved by the Dicer into shorter segments (21-23 nt) called small interfering RNA (siRNA). These siRNA then specifically target homologous mRNA molecules causing them to be degraded by cellular ribonucleases. RNAi down regulates endogenous gene expression in mammalian cells. Vascular endothelial growth factor (VEGF) is a key molecule in vasculogenesis as well as in angiogenesis. Tumor growth is an angiogenesis-dependent process, and therapeutic strategies aimed at inhibiting angiogenesis are theoretically attractive. To investigate the feasibility of using siRNA for VEGF in the specific knockdown of VEGF mRNA, thereby inhibiting angiogenesis, we have performed experiments with a DNA vector based on a siRNA system that targets VEGF (siVEGF). It almost completely inhibited the expression of three different isoforms (VEGF120, VEGF164 and VEGF188) of VEGF mRNA and the secretion of VEGF protein in mouse squamous cell carcinoma NRS-1 cells. The siVEGF released from cationized gelatin microspheres suppressed tumor growth in vivo. A marked reduction in vascularity accompanied the inhibition of a siVEGF-transfected tumor. Fluorescent microscopic study showed that the complex of siVEGF with cationized gelatin microspheres was still present around the tumor 10 days after injection, while free siVEGF had vanished by that time. siVEGF gene therapy increased the fraction of vessels covered by pericytes and induced expression of angiopoietin-1 by pericytes. These data suggest that cationized-gelatin microspheres containing siVEGF can be used to normalize tumor vasculature and inhibit tumor growth in a NRS-1 squamous cell carcinoma xenograft model. (Cancer Sci 2006; 97: 313 - 321).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16630124     DOI: 10.1111/j.1349-7006.2006.00174.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  8 in total

1.  Suppression of RNA interference pathway in vitro by Grass carp reovirus.

Authors:  Shuai Guo; Dan Xu; Hong-xu Xu; Tu Wang; Jia-le Li; Li-qun Lu
Journal:  Virol Sin       Date:  2012-04-11       Impact factor: 4.327

2.  Global gene expression profiling in cultured cells is strongly influenced by treatment with siRNA-cationic liposome complexes.

Authors:  Tatsuaki Tagami; Kiyomi Hirose; Jose Mario Barichello; Tatsuhiro Ishida; Hiroshi Kiwada
Journal:  Pharm Res       Date:  2008-06-26       Impact factor: 4.200

3.  Gene silencing following siRNA delivery to skin via coated steel microneedles: In vitro and in vivo proof-of-concept.

Authors:  Rosalind H E Chong; Emilio Gonzalez-Gonzalez; Maria F Lara; Tycho J Speaker; Christopher H Contag; Roger L Kaspar; Sion A Coulman; Rachel Hargest; James C Birchall
Journal:  J Control Release       Date:  2013-01-08       Impact factor: 9.776

4.  G2A as a Threshold Regulator of Inflammatory Hyperalgesia Modulates Chronic Hyperalgesia.

Authors:  Yeu-Shiuan Su; Yu-Fen Huang; Jen Wong; Chia-Wei Lee; Wei-Shan Hsieh; Wei-Hsin Sun
Journal:  J Mol Neurosci       Date:  2017-11-21       Impact factor: 3.444

5.  Involvement of the Reck tumor suppressor protein in maternal and embryonic vascular remodeling in mice.

Authors:  Ediriweera P S Chandana; Yasuhiro Maeda; Akihiko Ueda; Hiroshi Kiyonari; Naoko Oshima; Mako Yamamoto; Shunya Kondo; Junseo Oh; Rei Takahashi; Yoko Yoshida; Satoshi Kawashima; David B Alexander; Hitoshi Kitayama; Chiaki Takahashi; Yasuhiko Tabata; Tomoko Matsuzaki; Makoto Noda
Journal:  BMC Dev Biol       Date:  2010-08-06       Impact factor: 1.978

6.  TDAG8, TRPV1, and ASIC3 involved in establishing hyperalgesic priming in experimental rheumatoid arthritis.

Authors:  Wei-Shan Hsieh; Chia-Chi Kung; Shir-Ly Huang; Shih-Chang Lin; Wei-Hsin Sun
Journal:  Sci Rep       Date:  2017-08-21       Impact factor: 4.379

7.  TDAG8 involved in initiating inflammatory hyperalgesia and establishing hyperalgesic priming in mice.

Authors:  Shih-Ping Dai; Ya-Han Huang; Chung-Jen Chang; Yu-Fen Huang; Wei-Shan Hsieh; Yasuhiko Tabata; Satoshii Ishii; Wei-Hsin Sun
Journal:  Sci Rep       Date:  2017-02-01       Impact factor: 4.379

8.  Oncolytic adenovirus coexpressing interleukin-12 and shVEGF restores antitumor immune function and enhances antitumor efficacy.

Authors:  Hyo Min Ahn; JinWoo Hong; Chae-Ok Yun
Journal:  Oncotarget       Date:  2016-12-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.